1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Orphan Drugs for CNS Diseases: R&D and Market 2014-2024

Orphan Drugs for CNS Diseases: R&D and Market 2014-2024

  • January 2014
  • -
  • Visiongain
  • -
  • 130 pages

Report Details

Uncommon nerve disorders - new study explains technological and commercial prospects

What's the future of medicines for rare central nervous system (CNS) disorders? Visiongain's new report gives you predictions for those therapies. Stay ahead. There you explore sales results, technologies, R&D trends, opportunities, and revenue forecasts.

So see what's possible for treating unusual neurological conditions. Avoid missing out. You gain data and financial analysis for that industry and market, appraising its outlooks. Find technological progress and commercial prospects, seeing potential gains.

Read on to explore those treatments and find what their future could be worth.

Forecasts and other analyses for therapy of rare (orphan) neurodegenerative disorders

Our new study reveals sales predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.

Besides forecasting revenues to 2024, that work shows historical results, growth rates, and market shares. There you get feel for technologies, regulatory outlooks, and developments (R&D). You also gain 41 tables, 40 charts, and two interviews with the industry.

Knowledge to help your work and save time, helping your influence

Our report strives to help your business research, analyses, and decisions on treatments for debilitating CNS diseases. There also see how you can save time. And find how you could benefit your authority through better understanding the present and future.

So the following sections explain what you get in that new investigation.

Forecasting of that world market and its main segments - you explore possibilities

What're the secrets of that industry's progress? What's its potential? Discover in our work overall world revenue to 2024 for orphan-drug CNS therapy.

Also in that report you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:
- Huntington's disease (HD)
- Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease, motor neurone disease)
- Myasthenia gravis (MG)
- Other treatment applications.

How will those categories expand? Which classes of therapy can generate most money? So you assess outlooks for sales growth, seeing where you can gain.

There you explore competition and rising sales for treating the rarer abnormalities causing neurodegeneration, autoimmune neuromuscular disorder, and other nerve disease.

You also assess top products' futures.

Predictions of leading agents' revenues

Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for four marketed drugs:
- Xenazine (tetrabenazine)
- Rilutek (riluzole)
- Mestinon (pyridostigmine)
- Imuran (azathioprine).

There you find products and years with highest predicted sales and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and potentials.

Our study also divides its overall prediction into geographical regions.

Healthcare in leading national markets - what outlooks for those CNS drug sales?

In developed and developing countries, opportunities for providers of orphan neurological medicines will increase from 2014 to 2024. See where and how, finding sales potentials.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
- United States (US)
- Japan
- EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
- BRIC nations - Brazil, Russia, India, and China.

There you find countries with highest revenues, demand, and potential sales growth. Our work explains. You assess needs and demands for those specialist medicines.

Explore, too, how that neur

Table Of Contents

Orphan Drugs for CNS Diseases: RandD and Market 2014-2024
1. Executive Summary
1.1 Orphan Drugs for CNS Diseases: Market Overview
1.2 Report Contents - Chapter Overviews
1.3 Research and Analysis Methods

2. Introduction to Orphan Drugs for CNS Disorders
2.1 Defining Orphan Diseases
2.2 What are the Major Orphan CNS Indications?
2.2.1 Huntington's Disease
2.2.2 Amyotrophic Lateral Sclerosis (ALS)
2.2.3 Myasthenia Gravis
2.2.4 Other Orphan CNS Indications
2.3 Orphan Drug Designation: Providing Incentives to Companies
2.3.1 What Benefits Come with Orphan Drug Designation?
2.4 Demand for Orphan Drugs Gathers Momentum
2.4.1 Development of Orphan Drugs

3. The World Orphan CNS Drugs Market, 2014-2024
3.1 How Large Was the Orphan Drugs Market in 2013?
3.1.1 Huntington's Disease: The Largest Orphan CNS Disease Sector in 2012
3.2 The Orphan CNS Drug Market: Revenue Forecast, 2013-2024
3.2.1 What Will Drive Growth in the Market to 2024?
3.2.2 What Will Restrain the Market From 2014-2024?
3.3 Orphan Drugs in Huntington's Disease
3.3.1 Huntington's Disease: Submarket Forecast, 2013-2024
3.3.1.1 Huge Unmet Need to Drive HD Treatment Market
3.3.1.2 Enactment of New Law in US May Add Growth Impetus
3.4 Orphan Drugs in Amyotrophic Lateral Sclerosis
3.4.1 Amyotrophic Lateral Sclerosis: Submarket Forecast, 2013-2024
3.4.1.1 New Drug Launches Will Provide Market Recovery Following Patent Expiry of Rilutek
3.5 Orphan Drugs in Myasthenic Gravis
3.5.1 Myasthenia Gravis: Submarket Forecast, 2013-2024
3.5.1.1 Clinical RandD into New Treatments Keep Patients Hopeful

4. Leading National Markets for Rare CNS Indications 2014-2024
4.1 Regional Breakdown of The Orphan CNS Drug Market
4.2 Leading National Markets: Revenue Forecasts, 2013-2024
4.3 The US: The Leading Market for Orphan CNS Drugs in 2012
4.3.1 Orphan Drug Regulations in the US
4.3.2 Benefits for Orphan Drug Developers
4.3.3 The US Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4 Orphan Drugs in Leading EU Markets
4.4.1 The EU5 Orphan CNS Drug Market: Revenue Forecasting, 2013-2024
4.4.1.1 The Incentives for Orphan Drug Development in the EU
4.4.2 Orphan CNS Drugs in the EU5: Submarket Revenue Forecasts, 2013-2024
4.4.2.1 The German Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4.2.2 The French Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4.2.3 The UK Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4.2.4 The Spanish Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4.2.5 The Italian Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.5 The Japanese Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.5.1 Orphan Drug Regulations and Benefits in Japan
4.6 Potential for Orphan CNS Drugs in Emerging National Markets, 2013-2024
4.6.1 The Chinese Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.6.2 The Indian Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.6.2.1 Large Patient Population to Draw Drug Developers to India
4.6.3 The Russian Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.6.3.1 Attempts to Introduce Orphan Designation and Incentives 2010-2013
4.6.4 The Brazilian Orphan CNS Drug Market: Revenue Forecast, 2013-2024

5. Outlooks for Leading Orphan CNS Drugs 2014-2024
5.1 Huntington's Disease Treatments
5.1.1 Xenazine (Tetrabenazine; Lundbeck/Valeant Pharmaceuticals)
5.1.1.1 Omerus Pipeline HD Treatment Receives Orphan Designation
5.1.1.2 Xenazine: Revenue Forecast, 2013-2024
5.2 Amyotrophic Lateral Sclerosis Treatments
5.2.1 Rilutek (Riluzole; Covis Pharmaceuticals)
5.2.1.1 Patent Expiry to Cause Influx of Generic Treatments
5.2.1.2 Rilutek: Revenue Forecast, 2013-2024
5.3 Myasthenia Gravis Treatments
5.3.1 Mestinon (Pyridostigmine bromide; Valeant Pharmaceuticals)
5.3.1.1 Lack of Novel Treatments to Compete With Branded Drug
5.3.1.2 Mestinon: Revenue Forecast, 2013-2024
5.3.2 Imuran (Azathioprine; Prometheus Laboratories/Aspen Pharmacare)
5.3.2.1 Serious Adverse Events May Further Reduce Use of Imuran
5.3.2.2 Imuran: Revenue Forecast, 2013-2024

6. Orphan CNS Drugs: RandD Pipelines
6.1 Drugs in the Huntington's Disease Pipeline
6.1.1 ALN-HTT (Alnylam Pharmaceuticals/Medtronic Inc.): Drug-Device Combination Therapy
6.1.2 HD-02 (Avicena Group Inc.): Correcting the Body's Cellular Energy
6.1.3 CERE-120 (Ceregene Inc.): Delivering Neurotrophic Factors to Reverse Disease Process
6.1.4 Lead Compounds (Chaperone Therapeutics): Targeting Protein Misfolding
6.1.5 CX929 (Cortex Pharmaceuticals): Ampakine Treatment to Encourage Neuronal Growth
6.1.6 EPI-743 (Edison Pharmaceuticals): Redox Therapy in Preclinical Testing
6.1.7 GSK356278 (GSK): Respiration Treatment in Line for Additional HD Indication
6.1.8 Modified Antisense Oligo-Nucleotides (Isis Pharmaceuticals): Partnering with Roche to Aid Drug Discovery
6.1.9 NsG33 (Meteorin; NsGene A/S): Neurotrophic Protein Shown to Stimulate Neurite Growth in Preclinical Studies
6.1.10 LSD-1/MAO-B Inhibitor (Oryzon Genomics): Reducing Enzyme Activity May Provide Therapeutic Benefit
6.1.11 PBT2 (Prana Biotechnology): Targeting Metal-Protein Interactions to Reduce Protein Aggregation
6.1.12 PRO289 (Prosensa): Lowering Levels of Mutant Gene Proteins
6.1.13 RP103 (Raptor Pharmaceutical Corporation): Cysteamine Treatment Receives Orphan Designation
6.1.14 Zinc DNA Transcription Factors (Sangamo Biosciences/Shire AG): Switching Genes On and Off
6.1.15 Selisistat (SEN196; Siena Biotechnology): Orphan Drug Targeting Sirtuin Protein Inhibition in Phase II Development
6.1.16 Huntexil (Teva Pharmaceuticals): Neutralizing Dopaminergic Activity
6.2 Drugs in the Amyotrophic Lateral Sclerosis Pipeline, 2013
6.2.1 ALS-02, ALS-05 and ALS-08 (The Avicena Group): Designated Orphan Drug in Advanced Clinical Testing
6.2.2 NurOwnâ„¢ (BrainStorm Cell Therapeutics): Stem Cell Treatment to Replace Damaged Cells
6.2.3 Tirasemtiv (CK-2017357; Cytokinetics): Skeletal Muscle Activator Advances to Phase II Trials
6.2.4 E0302 (Mecobalamin; Eisai): Vitamin B12 Therapy Shown to Improve Muscle Wasting
6.2.5 Ozanezumab (GSK1223249; GSK): Monoclonal Antibody Treatment Recruiting Patients for Phase II Trial
6.2.6 Radicut (Edaravone; Mitsubishi Tanabe): Free Radical Scavenger in Advanced Trials
6.2.7 Region Specific Stem Cells (Neuralstem): Neuronal Stem Cell Therapy in Preclinical Testing
6.2.8 NP001 (Neuraltus Pharmaceuticals): Altering Macrophage Activity
6.2.9 sNN0029 (NeuroNova): Growth Factor Treatment Shown to Improve Muscle Strength
6.2.10 TDI-132 (Gilenyaâ„¢; Novartis and The ALS Therapy Development Institute): Therapy to Counteract Aggressive Immune Cells
6.3 Drugs in the Myasthenia Gravis Pipeline, 2013
6.3.1 Soliris® (Eculizumab; Alexion Pharmaceuticals): Blood Disorder Treatment Investigated as Potential MG Therapy
6.3.2 BHT-3034 (Bayhill Therapeutics): Vaccine Therapy to Reverse Harmful Immune Responses
6.3.3 BKT130 (Biokine Therapeutics): Chemokine Inhibitor
6.3.4 CK-2017357 (Tirasemtiv; Cytokinetics): Designated Orphan Drug Tested in Multiple Indications

7. Orphan Drugs in CNS: Industry Trends, 2014-2024
7.1 Orphan Drugs in CNS: Strengths and Weaknesses, 2013-2024
7.2 Orphan Drugs in CNS: Opportunities and Threats, 2013-2024
7.3 Orphan Drugs in CNS: STEP Analysis, 2013-2024
7.3.1 Social Factors
7.3.1.1 Ethical Considerations in Funding Orphan Drug Development
7.3.2 Technological Developments
7.3.2.1 Increased Understanding of Disease Will Drive Innovation
7.3.3 Economic Pressures
7.3.3.1 Discounts in Drug Prices Will Increase Accessibility
7.3.4 Political Issues
7.3.4.1 Harmonising Global Regulatory Pathways
7.4 Trends in Orphan CNS Drug Development
7.4.1 Clinical Trials for Orphan Drugs
7.4.1.1 Are Adverse Events More Acceptable for Orphan Drugs?
7.4.1.2 Challenges and Opportunities in Patient Recruitment
7.4.2 Biomarkers for Orphan CNS Indications
7.4.2.1 Companion Diagnostics: Driving Personalised Medicine
7.4.3 The Role of Public Funding in Orphan Drug Development
7.5 Commercialising Orphan Drugs in CNS
7.5.1 Pricing of Orphan Drugs May Become Crucial to Success
7.5.2 Market and Patient Access Are Crucial for Orphan Drug Success
7.5.3 Repositioning Drugs for Orphan CNS Indications
7.5.3.1 Expanding Beyond Orphan Indications
7.5.4 Big Pharma and Orphan Drugs
7.5.4.1 Orphan Drugs Fit the Personalised Medicine Model
7.5.5 Common Market Entry Strategies
7.5.6 Orphan Indications as an Opportunity for Generic Drug Manufacturers

8. Research Interviews
8.1 Dr Tsao-Nivaggioli, CEO and Board Member, Avicena Group
8.1.1 Avicena Group
8.1.2 Rare Diseases and Applying for Orphan Drug Status
8.1.3 HD-02: Targeting the Body's Cellular Energy Systems
8.1.4 Challenges in Developing Orphan Drugs
8.1.5 Future Growth Opportunities and Perspective for the Market
8.2 Respondent from Edison Pharmaceuticals
8.2.1 Edison Pharmaceuticals
8.2.2 Defining Orphan Disease and Drug Submissions in Target Markets
8.2.3 The Market Potential (and Risk) of Pursuing Treatments for Mitochondrial Diseases
8.2.4 Company Alliances and Future Prospects for the Market

9. Conclusions from Our Study
9.1 The State of the Orphan CNS Drugs Market
9.2 Renewed Interest in Rare CNS Diseases will Stimulate that Market
9.3 The US will Maintain its Market Dominance from 2014-2024
9.4 High Price of Treatments May Limit Market Potential

List of Tables
Table 1.1 Currency Exchange Rates
Table 1.2 Common Abbreviations Used in this Report
Table 2.1 EU Prevalence Statistics for Selected Rare CNS Indications, 2013
Table 3.1 Global Orphan CNS Drug Market: Revenue ($m) and Market Share (%) by Sector, 2012
Table 3.2 Global Orphan CNS Drug Market: Overall Market and Revenue Forecasts by Sector ($m, AGR %, CAGR %), 2013-2024
Table 3.3 Global Orphan CNS Drug Market: Submarket Shares (%), 2012-2024
Table 3.4 Huntington's Disease Submarket: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.5 Amyotrophic Lateral Sclerosis Submarket: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.6 Myasthenia Gravis Submarket: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.1 Global Orphan CNS Drug Market: Revenue ($m) and Market Share (%) by Region, 2012
Table 4.2 Global Orphan CNS Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Region, 2013-2024
Table 4.3 Global Orphan CNS Drug Market: Regional Submarket Shares (%),2012-2024
Table 4.4 US Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.5 EU5 Orphan CNS Drug Market: Revenue ($m) and Market Share (%) by Country, 2012
Table 4.6 EU5 Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %) by Country, 2013-2024
Table 4.7 Fee Reductions (%) Available for SMEs Developing Orphan Drugs in the EU, 2013
Table 4.8 German Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.9 French Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.10 UK Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.11 Spanish Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.12 Italian Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.13 Japanese Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.14 Chinese Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.15 Indian Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.16 Russian Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.17 Brazilian Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.1 Top Orphan CNS Drugs: Revenues ($m) and Leading Revenue Shares (%), 2012
Table 5.2 Xenazine: Revenue ($m), 2009-2012
Table 5.3 Xenazine: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.4 Rilutek: Revenue ($m), 2010-2012
Table 5.5 Rilutek: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.6 Mestinon: Revenue ($m), 2010-2012
Table 5.7 Mestinon: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.8 Imuran: Revenue ($m), 2008-2012
Table 5.9 Imuran: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 6.1 Selected Pipeline Candidates in Development for Huntington's Disease, 2012
Table 6.2 Selected Pipeline Candidates in Development for ALS, 2013
Table 6.3 Selected Pipeline Candidates in Development for Myasthenia Gravis, 2013
Table 7.1 Global Orphan CNS Drug Market: Strengths and Weaknesses, 2013-2024
Table 7.2 Global Orphan CNS Drug Market: Opportunities and Threats, 2013-2024
Table 9.1 Global Orphan CNS Drug Market: Revenue ($m, CAGR %), and Market Share (%) by Sector, 2012, 2018 and 2024
Table 9.2 Global Orphan CNS Drug Market: Revenue ($m, CAGR %) and Market Share (%) by Region, 2012, 2018 and 2024

List of Figures
Figure 2.1 Orphan Disease Prevalence by Country/Region, 2013
Figure 2.2 Orphan Drugs Clinical Pipeline by Therapeutic Category, 2012
Figure 2.3 Orphan Drug Designation Benefits in Major Markets, 2013
Figure 3.1 Orphan Drug Approvals in the US, 2000-2013
Figure 3.2 Global Orphan CNS Drug Market: Share (%) by Sector, 2012
Figure 3.3 Global Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 3.4 Global Orphan CNS Drug Market: Submarket Shares (%), 2018
Figure 3.5 Global Orphan CNS Drug Market: Submarket Shares (%), 2024
Figure 3.6 Global Orphan CNS Drug Market: Drivers and Restraints, 2014-2024
Figure 3.7 Huntington's Disease Market: Revenue Forecast ($m), 2013-2024
Figure 3.8 Amyotrophic Lateral Sclerosis Market: Revenue Forecast ($m), 2013-2024
Figure 3.9 Myasthenia Gravis Market: Revenue Forecast ($m), 2013-2024
Figure 4.1 Global Orphan CNS Drug Market: Share (%) by Region, 2012
Figure 4.2 Global Orphan CNS Drug Market: Share (%) by Region, 2018
Figure 4.3 Global Orphan CNS Drug Market: Share (%) by Region, 2024
Figure 4.4 US Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.5 EU5 Orphan CNS Drug Market: Share (%) by Country, 2012
Figure 4.6 EU5 Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.7 German Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.8 French Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.9 UK Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.10 Spanish Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.11 Italian Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.12 Japanese Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.13 Chinese Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.14 Indian Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.15 Russian Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.16 Brazilian Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 5.1 Top Orphan CNS Drug: Revenue Shares (%), 2012
Figure 5.2 Xenazine: Revenue ($m), 2009-2012
Figure 5.3 Xenazine: Revenue Share (%) by Region, 2012
Figure 5.4 Xenazine: Revenue Forecast ($m), 2013-2024
Figure 5.5 Rilutek: Revenue ($m), 2010-2012
Figure 5.6 Rilutek: Revenue Forecast ($m), 2013-2024
Figure 5.7 Mestinon: Revenue ($m), 2010-2012
Figure 5.8 Mestinon: Revenue Forecast ($m), 2013-2024
Figure 5.9 Imuran: Revenue ($m), 2008-2012
Figure 5.10 Imuran: Revenue Forecast ($m), 2013-2024
Figure 9.1 Global Orphan CNS Drug Market: Revenue ($m) by Sector, 2012, 2018 and 2024
Figure 9.2 Global Orphan CNS Drug Market: Revenue ($m) by Region, 2012, 2018 and 2024

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market and Infectious Disease Statistics in the US

  • January 2017
    52 pages
  • Anti-Infective  

    Infectious Dise...  

    Vaccine  

  • United States  

View report >

Anti-Infective Market

  • January 2017
  • Anti-Infective  

View report >

Cardiovascular Drug Market

  • January 2017
    14 pages
  • Cardiovascular ...  

    Therapy  

    Endocrine Disea...  

View report >

Therapy Market

29 hours ago

Laparoscope Industry

29 hours ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.